Neogen Corporation Revenue per Employee (NEOG), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Neogen Corporation  (NASDAQ: NEOG)
 

Neogen's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 6.67% in the first quarter 2026, year on year to cumulative value of $884 million, Neogen's revenue per employee grew on a trailing twelve months basis to $ 335,402. The productivity of Neogen's employees was 0.0%, above the company average.
Within the Healthcare sector Employees of 287 other companies have achieved higher revenue per employee. While Neogen's total ranking has deteriorated compared to the previous quarter from 2358 to 2364. Neogen has 2,636 employees.


What is Sales per Employee Ratio?







NEOG Revenue per Employee (Aug 31 2026)
I. Quarter
(May 31 2026)
IV. Quarter
(Feb 28 2026)
III. Quarter
(Nov 30 2025)
II. Quarter
(Aug 31 2025)
I. Quarter
Y / Y Revenue Change 6.67 % -0.58 % -4.21 % -2.45 % -3.67 %
Sales per Employee (TTM) $ 335,402 330,118 330,618 334,133 336,275
NEOG's Total Ranking # 2364 # 2358 # 57 # 36 # 23
Seq. Revenue Change -1.17 % 6.89 % -6.09 % 7.52 % -7.88 %


Revenue per Employee Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 5
Healthcare Sector # 288
Overall Market # 2364

Revenue per Employee Statistics
High Average Low
$ 351,893 $ 187,510 $ 69,820
(Feb 29 2024)   (May 31 2012)



Financial Statements
Neogen's Revenue MRQ $ 223 Millions Visit NEOG's Income Statement
Neogen's Revenues TTM $ 884 Millions Visit NEOG's aggregate revenue growth
What are NEOG's Sales? Visit NEOG's Sales by Segment


  News about Neogen Corporation Revenue per employee

Investor Alert Pomerantz Law Firm Investigates Potential Claims Against Neogen Corporation Amid Concerns of M...

New York, September 6, 2025 In a significant development for shareholders of Neogen Corporation (NASDAQ: NEOG), the Pomerantz Law Firm has announced that it is investigating potential claims on behalf of investors who may have suffered losses in their investment in the Company. This news comes as Neogen has been under scrutiny, prompting legal experts to assess whether the company’s actions may have led to breaches of fiduciary duty or other violations of investor rights.Neogen Corporation, a prominent player in food safety and animal health industries, has traditionally been recognized for its innovative products and services that help ensure the safety of food and animal products. However, recent events have raised concerns regarding its operational practices and financial reporting standards. The Pomerantz Law Firm’s proactive investigation is a response to these emerging uncertainties and seeks to assist investors seeking recourse for any potential damages incurred.




Other Ratios
Neogen's Income per Employee
Employees in In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NEOG's Revenue per Employee versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NEOG's Competitors
Revenue per Employee for NEOG's Suppliers
Revenue per Employee for NEOG's Customers

You may also want to know
NEOG's Sales Growth Rates NEOG's Pe Price to earnings ratio NEOG's Receivables Turnover Ratio NEOG's Stock Quote
NEOG's Net Income Growth Rates NEOG's Ps Price to Sales ratio NEOG's Sales per Employee NEOG's Asset Turnover Ratio
NEOG's Net Margin NEOG's Pb Price to Book ratio NEOG's Financial Strength Ratios NEOG's Dividend Payout Ratio
Date modified: 2026-10-08T04:22:54+00:00




Companies with similar Revenue per Employee for 12 months ending Aug 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Aug 31 2026Number of Employees Aug 31 2026
Butterfly Network Inc   562,340.91 $ 123.715  Million 220 
Novavax inc   549,598.13 $ 411.649  Million 749 
Henry Schein Inc   549,360.00 $ 13,734.000  Million 25,000 
Bausch Health Companies Inc   547,438.42 $ 11,113.000  Million 20,300 
Iradimed Corporation  538,192.16 $ 89.340  Million 166 
Glaukos Corp  528,660.88 $ 578.355  Million 1,094 
Angiodynamics Inc   512,316.46 $ 323.784  Million 632 
Resmed Inc   505,115.57 $ 5,743.164  Million 11,370 
Avantor Inc   491,525.93 $ 6,635.600  Million 13,500 
Lexicon Pharmaceuticals Inc   475,765.43 $ 38.537  Million 81 
Stryker Corp  469,642.86 $ 26,300.000  Million 56,000 
Monte Rosa Therapeutics Inc   468,833.33 $ 70.325  Million 150 
Dexcom Inc   459,900.90 $ 5,104.900  Million 11,100 
Medpace Holdings Inc   457,804.03 $ 2,838.385  Million 6,200 
Haemonetics Corporation  457,405.56 $ 1,382.737  Million 3,023 
Novocure Limited  451,955.14 $ 725.388  Million 1,605 
Omniab Inc   451,808.99 $ 40.211  Million 89 
Teladoc Health Inc   440,739.82 $ 2,468.143  Million 5,600 
Orthopediatrics Corp  437,981.73 $ 263.665  Million 602 
Vanda Pharmaceuticals Inc   430,165.10 $ 229.278  Million 533 
Axogen inc   429,141.48 $ 266.926  Million 622 
Idexx Laboratories Inc  423,970.45 $ 4,663.675  Million 11,000 
3m Company  417,305.79 $ 25,247.000  Million 60,500 
Bausch and Lomb Corp  416,769.23 $ 5,418.000  Million 13,000 
Regenxbio Inc   414,854.45 $ 153.911  Million 371 
Teva Pharmaceutical Industries Limited  412,960.24 $ 14,020.000  Million 33,950 
Lemaitre Vascular Inc   412,119.08 $ 269.938  Million 655 
Sotera Health Company  410,083.33 $ 1,230.250  Million 3,000 
Cryo cell International Inc   409,559.89 $ 31.127  Million 76 
Innovage Holding Corp   407,343.60 $ 1,018.359  Million 2,500 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.